Skip to content
Triangle logo TriangleGet started
← Study library

NCT01155583 · REGISTRY CONDITION SEARCH

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2020-11-16

RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving azacitidine together with lenalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of azacitidine when given together with lenalidomide and low-dose dexamethasone in treating patients with relapsed or refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase I: Highest Tolerated Low Dose (HTLD)

→

outcome · POSTED

Percent of Participants With Clinical Benefit and Response According to International Response Criteria

→

outcome · POSTED

Percent of Participants With Clinical Benefit and Response According to International Response Criteria

→

outcome · POSTED

Median Progression-free Survival (PFS)

→

outcome · POSTED

Overall Survival

→

outcome · NOT POSTED

Changes in Global Gene Expression

→

outcome · NOT POSTED

Quantify the Activity of Azacitidine Inactivating Enzyme Cytidine Deaminase (CDA)

→

outcome · NOT POSTED

Promoter Demethylation and Gene Reactivation

→

outcome · NOT POSTED

CD34+ Cell Yield and Time to Neutrophil and Platelet Recovery

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Understand and voluntarily sign an informed consent form * Able to adhere to the study visit schedule and other protocol requirements * Refractory or relapsed multiple myeloma * Measurable disease defined as at least one of the following: Serum m-spike ≥ 1g/dL, urine m-spike ≥ 200mg/24hrs, serum free light chains ≥ 100mg/L (provided the kappa/lambda ratio is abnormal), or bone marrow plasma cells ≥ 30% * Previous therapy with IMiD™ compounds (thalidomide, lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, carfilzomib), and corticosteroids must be discontinued at least 14 days before entry onto this study. * Previous cytotoxic chemotherapy (e.g. alkylating chemotherapy, anthracyclines, and vinca alkaloids), radiation therapy to the pelvis, and any experimental therapy other than carfilzomib or pomalidomide must have been discontinued at least 28 days prior to entry onto this study. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 at study entry. * Laboratory test results within these ranges: * Absolute neutrophil count ≥ 1,500 /mm³ * Platelet count ≥ 75,000/mm³ * Calculated creatinine clearance (Cockcroft-Gault) ≥ 30ml/min. * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) levels ≤2 x ULN * All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®. * Females of childbearing potential (FCBP)must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. * Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin) if no additional risk factor for venous thromboembolic event (VTE) other than myeloma diagnosis according to IMW guidelines * Able to take low molecular weight heparin or warfarin if ≥ 1 additional risk factor for VTE according to IMW guidelines Exclusion Criteria: * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form * Pregnant or breast feeding females (Lactating females must agree not to breast feed while taking lenalidomide or azacitidine) * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study * Use of any experimental drug or therapy other than carfilzomib and pomalidomide within 28 days of treatment start on this protocol. * Neuropathy \> Grade 2 * Known hypersensitivity to thalidomide, lenalidomide, azacitidine, or mannitol * The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or lenalidomide drugs * Concurrent use of other anti-cancer agents or treatments, concurrent radiation to the pelvis. Palliative radiation to areas outside the pelvis is allowed * Previous inability to tolerate full-dose lenalidomide, adjusted to creatinine clearance (CrCl) according to Cockcroft-Gault at the time of previous lenalidomide treatment (25mg day 1-21 every 28 days if CrCl \> 60ml/min, 10mg lenalidomide d1-21 every 28 days if CrCl \< 60mL/min but \> 30mL/min, lenalidomide 15mg every 48 h d1-21 every 28 days if CrCl \< 30mL/min but not requiring dialysis, lenalidomide 5mg daily, day 1-21 every 28 days if CrCl \< 30mL/min and requiring dialysis).
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Dose Level (DL) 1 - Azacitidine 30mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week DL 2 - Azacitidine 40mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week DL 3 - Azacitidine 30mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week DL 4 - Azacitidine 40mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week DL 5 - Azacitidine 50mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week Patients (with GFR \> 60 ml/min) receive azacitidine subcutaneously 1 or 2x per weekly and oral Dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: azacitidine
    2. Drug: lenalidomide
    3. Drug: dexamethasone
    4. Other: DNA methylation analysis
    5. Other: gene expression analysis
    6. Other: bone marrow aspiration
    7. Other: immunohistochemistry staining method
    8. Other: reverse transcriptase-polymerase chain reaction
    9. Other: flow cytometry
    label
    Arm A - Azacitidine/Lenalidomide/Dexamethasone
    type
    EXPERIMENTAL
  2. description
    DL (-1) - Azacitidine 30mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week DL 1 - Azacitidine 40mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week DL 2 - Azacitidine 50mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week Patients (with GFR 30-59 ml/min Chronic Kidney Disease (CKD)) receive azacitidine subcutaneously 1 or 2x per weekly and oral dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: azacitidine
    2. Drug: lenalidomide
    3. Drug: dexamethasone
    4. Other: DNA methylation analysis
    5. Other: gene expression analysis
    6. Other: bone marrow aspiration
    7. Other: immunohistochemistry staining method
    8. Other: reverse transcriptase-polymerase chain reaction
    9. Other: flow cytometry
    label
    Arm B - Chronic Kidney Disease (CDK) Cohort
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Given by subcutaneous injection (SC)
    name
    azacitidine
    other Names
    1. 5-AC
    2. 5-azacytidine
    3. 5-AZC
    4. azacytidine
    5. ladakamycin
    6. Vidaza
    type
    DRUG
  2. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Given orally
    name
    lenalidomide
    other Names
    1. CC-5013
    2. IMiD-1
    3. Revlimid
    type
    DRUG
  3. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Given orally
    name
    dexamethasone
    other Names
    1. Aeroseb-Dex
    2. Decaderm
    3. Decadron
    4. Decaspray
    5. DM
    6. DXM
    type
    DRUG
  4. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Correlative studies
    name
    DNA methylation analysis
    type
    OTHER
  5. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Correlative studies
    name
    gene expression analysis
    type
    OTHER
  6. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Correlative studies
    name
    bone marrow aspiration
    type
    OTHER
  7. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Correlative studies
    name
    immunohistochemistry staining method
    other Names
    1. immunohistochemistry
    type
    OTHER
  8. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Correlative studies
    name
    reverse transcriptase-polymerase chain reaction
    other Names
    1. RT-PCR
    type
    OTHER
  9. arm Group Labels
    1. Arm A - Azacitidine/Lenalidomide/Dexamethasone
    2. Arm B - Chronic Kidney Disease (CDK) Cohort
    description
    Correlative studies
    name
    flow cytometry
    type
    OTHER
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
45
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    The RNA harvested from myeloma cells before and after the first cycle of therapy at the HTLD level will furthermore be used to identify changes in global gene expression using the Illumina® HT12 array.
    measure
    Changes in Global Gene Expression
    time Frame
    before and after the first cycle of therapy
  2. description
    Plasma from peripheral blood draws will be used to quantify the activity of CDA using an HPLC method.The enzymatic activity is determined by comparison of cytidine deamination achieved by plasma samples with deamination achieved by incubation of cytidine with dilutions of pure CDA enzyme standards.
    measure
    Quantify the Activity of Azacitidine Inactivating Enzyme Cytidine Deaminase (CDA)
    time Frame
    at 6 months
  3. description
    Promoter demethylation and gene reactivation will be measured at least at the HTLD level using the Illumina® HumanMethylation27 BeadChip array on CD138 purified and CD34 purified cells obtained from bone marrow aspirates
    measure
    Promoter Demethylation and Gene Reactivation
    time Frame
    within 7 days before treatment start and at the end of cycle #1
  4. description
    CD34+ cell yield will be calculated based on flow cytometry of mononuclear cells harvested following stem cell mobilization. Time to neutrophil (\> 1,000/mm3) and platelet (\> 100,000/mm3) recovery will be counted from the day of stem cell infusion (=day 0)
    measure
    CD34+ Cell Yield and Time to Neutrophil and Platelet Recovery
    time Frame
    after cycle 1 (28 days)
primary Outcomes
  1. description
    Azacitidine given at low but increasing doses up to 50mg/m2 twice a week. Maximum tolerated dose reported.
    measure
    Phase I: Highest Tolerated Low Dose (HTLD)
    time Frame
    During the first 28-day cycle
secondary Outcomes
  1. description
    Percent of participants with response according to international response criteria (\>= PR) and percent of participants with clinical benefit response (\>= minor response according to adapted EBMT criteria). Determined with serum and 24 hour urine protein electrophoresis, and as appropriate, supplemented by immunofixation, serum free light chain assay, and bone marrow examination. Response before high dose melphalan and autologous stem cell transplant will also be confirmed by two separate blood and 24 hour urine tests between the last dose of combination therapy and the first dose of the mobilizing agent.
    measure
    Percent of Participants With Clinical Benefit and Response According to International Response Criteria
    time Frame
    at 6 months
  2. description
    Percent of participants with response according to international response criteria (\>= PR) and percent of participants with clinical benefit response (\>= minor response according to adapted EBMT criteria). Determined with serum and 24 hour urine protein electrophoresis, and as appropriate, supplemented by immunofixation, serum free light chain assay, and bone marrow examination. Response before high dose melphalan and autologous stem cell transplant will also be confirmed by two separate blood and 24 hour urine tests between the last dose of combination therapy and the first dose of the mobilizing agent.
    measure
    Percent of Participants With Clinical Benefit and Response According to International Response Criteria
    time Frame
    at 12 months
  3. description
    Median PFS, measured in months from study entry to progression as defined by international response criteria or death of any cause, whichever comes first
    measure
    Median Progression-free Survival (PFS)
    time Frame
    Up to 3 years
  4. description
    Overall survival will be measured from study entry to death from any cause - median months survival will be reported
    measure
    Overall Survival
    time Frame
    up to 3 years
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving azacitidine together with lenalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of azacitidine when given together with lenalidomide and low-dose dexamethasone in treating patients with relapsed or refractory multiple myeloma.
detailed Description
PRIMARY OBJECTIVES: Define the highest tolerated low dose (HTLD) and safety of azacitidine given at low but increasing doses up to 50mg/m2 twice a week concurrently with Glomerular filtration rate (GFR)-adjusted lenalidomide and low dose dexamethasone in patients with relapsed or refractory multiple myeloma. SECONDARY OBJECTIVES: * Response according to international response criteria (≥PR) and clinical benefit response (≥minor response according to adapted EBMT criteria) * Correlate response with plasma activity of the azacitidine inactivating enzyme cytidine deaminase (CDA) * Progression-free survival and overall survival * Peripheral blood hematopoietic progenitor (CD34+) yield and time to neutrophil and platelet recovery in patients undergoing autologous stem cell transplantation * Promoter demethylation and gene reactivation in myeloma cells and hematopoietic progenitors treated at the HTLD / HTLD-CKD level after cycle 1 * Changes in global gene expression in myeloma cells treated at the HTLD / HTLD-CKD level after cycle 1 OUTLINE: This is a phase I, dose-escalation study of azacitidine followed by a phase II study. Patients receive azacitidine subcutaneously once or twice weekly and oral dexamethasone once weekly starting on day 1. Patients also receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-525efbff1c717fbeb2c3
      requested nct id
      NCT01155583
      primary nct id
      NCT01155583
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      7956f7907fa090563312bdcf58afc3710570635aa5eb3640e8e32163ca26bef9
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-525efbff1c717fbeb2c3
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01155583
      occurrences
      1. context exact
        NCT01155583
        end
        11
        exact text
        NCT01155583
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/906/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      29c52c4c5dc10e376a7b3e4c015f0d19546b1dd0d54371fde32bb19f54ace72e

    Preserved source evidence · Not medical advice